Amerigen Pharmaceuticals Inc. is recalling approximately 4,323 bottles of Temozolomide (20 mg and 180 mg), a prescription medication used in chemotherapy. The recall was issued because the capsules failed dissolution testing, meaning the medication may not dissolve and release into the body at the required rate. This defect could potentially make the treatment less effective than intended. Consumers should check their prescription bottles to see if they have the affected lot numbers.
The failure to meet dissolution specifications means the medication may not be absorbed properly by the body. This could result in a patient receiving an incorrect dose of their chemotherapy treatment, potentially impacting the management of their medical condition.
Drug recall baseline remedy
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.